MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Legend Biotech Corp ADR

Chiusa

SettoreSettore sanitario

33.29 5.75

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

30.96

Massimo

33.51

Metriche Chiave

By Trading Economics

Entrata

161M

41M

Vendite

26M

187M

EPS

0.14

Margine di Profitto

21.719

Dipendenti

2,600

EBITDA

162M

52M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+164.47% upside

Dividendi

By Dow Jones

Utili prossimi

12 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-30M

6.4B

Apertura precedente

27.54

Chiusura precedente

33.29

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Legend Biotech Corp ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2024, 11:36 UTC

Utili

Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales

11 mar 2025, 11:09 UTC

Utili

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 mar 2025, 11:08 UTC

Utili

Legend Biotech 4Q EPS 7c >LEGN

11 mar 2025, 11:00 UTC

Utili

Legend Biotech 4Q Rev $186.5M >LEGN

12 nov 2024, 12:06 UTC

Utili

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 nov 2024, 12:05 UTC

Utili

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 nov 2024, 12:00 UTC

Utili

Legend Biotech 3Q Rev $160.2M >LEGN

9 ago 2024, 11:02 UTC

Utili

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9 ago 2024, 11:01 UTC

Utili

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9 ago 2024, 11:01 UTC

Utili

Legend Biotech 2Q Loss/Shr 5c >LEGN

9 ago 2024, 11:00 UTC

Utili

Legend Biotech 2Q Rev $186.5M >LEGN

26 lug 2024, 11:01 UTC

Utili

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

13 mag 2024, 11:02 UTC

Utili

Legend Biotech 1Q Loss/Shr 16c >LEGN

13 mag 2024, 11:02 UTC

Utili

Legend Biotech 1Q Research and Development Expenses $101.0M >LEGN

Confronto tra pari

Modifica del prezzo

Legend Biotech Corp ADR Previsione

Obiettivo di Prezzo

By TipRanks

164.47% in crescita

Previsioni per 12 mesi

Media 83.36 USD  164.47%

Alto 95 USD

Basso 62 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Legend Biotech Corp ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

13

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

31.39 / 35.05Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.